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Abstract
Insights into tau molecular structures have advanced significantly in recent years. This field has been the subject of
recent breakthroughs, including the first cryo-electron microscopy structures of tau filaments from Alzheimer’s and
Pick’s disease inclusions, as well as the structure of the repeat regions of tau bound to microtubules. Tau structure
covers various species as the tau protein itself takes many forms. We will here address a range of studies that help to
define the many facets of tau protein structures and how they translate into pathogenic forms. New results shed light
on previous data that need now to be revisited in order to up-date our knowledge of tau molecular structure. Finally,
we explore how these data can contribute the important medical aspects of this research - diagnosis and therapeutics.
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Introduction
The investigation of tau molecular structure covers its
primary sequence, local elements of secondary structure
and global fold and, finally, complex formation and aggre-
gation. Tau is defined as an intrinsically disordered protein
(IDP) and is present as six isoforms in human brain (ran-
ging from 352 to 441 amino acid residues, Fig. 1), resul-
ting from alternative splicing [53, 63]. All these isoforms
are themselves subjected to multiple post-translational
modifications (PTMs), the best studied being phosphory-
lation. Its PTMs are incredibly complex because they are
numerous and can combine in many ways [105] and these
are also prone to cross-talk [20, 85, 86]. To make matters
even more complex, tau proteins are subjected to proteo-
lytic degradation [33, 171]. Ratios of isoforms [37], level of
phosphorylation and proteolytic degradation all contribute
to normal and pathological tau activity. Tau has many
binding partners, and is most notoriously bound to micro-
tubules (MTs) [49, 73, 76, 93, 150, 162, 167], but also to
many regulatory proteins [90, 115], DNA [17, 122] or mem-
brane [2]. The later non-standard functions of tau were pre-
viously reviewed following EuroTau 2017 gathering [141].
Tau is associated with several neurodegenerative diseases,
termed tauopathies, in which it is found as insoluble de-
posits associated with other cellular components [13]. Tau
is the principal component of paired helical filaments
(PHFs) and straight filaments (SFs) [23, 54], which form the
intraneuronal fibrillar deposits known as neurofibrillary
tangles (NFT) in Alzheimer’s disease (AD) and leading
ultimately to neurofibrillary degeneration. The tau filaments
have cross-β structure and therefore share the common
characteristics of amyloid [18]. The aggregates themselves
are not a single homogenous family. In addition to mature
insoluble aggregates, which have different disease-specific
structures, tau is found as oligomeric forms, loosely
defined, but thought to have a very toxic effect [42, 62].
Thus, inhibition and/or clearance of oligomeric hyper-
phosphorylated tau could be a more effective therapeutic
target than the fibrilized protein [82, 143]. Because tau fila-
ments were thought to be composed of the microtubule
binding region (MTBR, Fig. 1), it has been common prac-
tice to use tau fragments containing only this region, either
in its 3R (isoform containing 3 repeat domains) version
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(K19) or 4R (isoform containing 4 repeat domains) version
(K18), as model peptides for aggregation studies. Two
homologous hexapeptides named PHF6* (275VQIINK280)
and PHF6 (306VQIVYK311) located at the start of the se-
cond and third repeat regions (R2 and R3) (Fig. 1) of tau
MTBR, respectively, are essential for tau aggregation
[157]. PHF6* is thought to be the stronger driver of aggre-
gation [135]. PHF6(*) (PHF6* and PHF6) peptides spon-
taneously aggregate in solution in contrast to the full-
length tau which is a highly soluble protein. The atomic
structures of the two hexapeptides reveal the capacity of
these segments to form interdigitated steric-zipper inter-
faces that seed tau aggregation [79, 131, 135].
To grasp the molecular characteristics of tau structures is
challenging. First of all, as a large IDP, tau is flexible and dy-
namic and requires high-field nuclear magnetic resonance
spectroscopy (NMR) to collect molecular detail. Tau has a
low complexity amino-acid sequence, and recently joined
the club of proteins with the capacity to form liquid drop-
lets [8]. More than an oddity, it seems that this form of tau
is able to seed MTs assembly in a highly efficient manner
and might have consequences for aggregation initiation [8,
161]. Aggregates are solid and heterogeneous, and therefore
are challenging to characterize by classical structural tech-
niques. Finally, the molecular details of tau interaction with
MTs are difficult to define due to the dynamic nature of the
complex, the MTs being by themselves in dynamic equi-
librium. Progress in understanding the mechanistic role
of tau as a microtubule associated protein came from
cryo-electron microscopy (cryo-EM), which offered a
view of tau repeats bound to MTs [76]. Recent break-
throughs, detailed in this review, came from progress in
sophisticated biophysical techniques brought together
with immense efforts and ingenuity.
We here will focus on tau molecular structures, highligh-
ting the techniques required for its characterization, and
summarizing the results that may provide basis for a better
definition of tau pathological forms and the pathway(s) of
pathogenesis. Finally, we conclude by showing how these
results can translate into better targeted tau-antibodies for
diagnostic and into progress in tau imaging. This review
does not intend to be a full-coverage of the literature but
rather to reflect the lively discussion that took place on the
EuroTau meeting 2018, in Lille, France.
Aggregate structure: From heparin-induced structure to
native conformation
The characterization of amyloid structures is challenging
because they are only partially ordered and often hetero-
geneous. Crystallization has been possible for short pep-
tides [125, 135], but not for full-length proteins. Because
of this lack of precise structural information, the relation-
ship between amyloid structure and pathology remains a
heated debate for many proteins; tau is no exception.
The large majority of structural studies in the last few
decades have been carried out on aggregates made out of
recombinant tau constructs. Limited proteolysis applied on
K18, K19 and the full-length tau2N4R showed that the
amyloid core is formed by the second half of R1, R2 (when
present), R3 and the first half of R4 [156]. Solid-state NMR
(ssNMR) confirmed that, in K19, β-sheets are formed in
the end of R1, in the full R3 and the beginning of R4 [12].
Another ssNMR study showed more precisely that only 19
residues, 306–324, formed β-sheets while the rest remains
relatively dynamic [29], in agreement with proton/deu-
terium exchange experiments. They also showed that the
packing is in-register and parallel, confirming what was ob-
served earlier by electron paramagnetic resonance (EPR)
spectroscopy [91]. Furthermore, Bibow and co-workers
[19] showed that the N- and C-termini (0–212, 399–441)
are highly mobile while the central region is too immobile
to be detected by solution NMR. They also show
electrostatically-driven long-range interactions between the
filament core and both C- and N-terminal extremity.
Fig. 1 Scheme of tau showing domain organization. Depending of the isoform, tau has an N-terminal extension with 0, 1, or 2 inserts (tau0N, tau1N,
tau2N, respectively), the presence of N1 and N2 inserts depending on exon 2 and exon 3, respectively. The microtubule-binding region (MTBR) has
three (tau3R) or four (tau4R) repeats, the presence of R2 depending on exon 10. MTBR repeats R1 to R4 (31 or 32 residues for each repeat and inter-
repeat region) have similar sequences. The PHF6* and PHF6 peptides are located in R2 and R3, respectively. The longest tau isoform corresponds to
441 amino-acid residues (or tau2N4R) and the shortest to tau352 amino-acid residues (or tau0N3R). Tau fragments K18, K19 and dGAE are mentioned
in the text. The proline-rich region or PRR has many phosphorylation sites, combination of pS202/pT205 and pS208 forms the AT8 monoclonal
antibody epitope. Antibody 18F12 recognizes a conformational epitope at the junction of N1 and N2 inserts. The 18–28 motif of tau is primate specific
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While recombinant filaments have shed light on many
aspects of tau aggregation mechanisms and structure, it
is important to note that their formation presents poten-
tial biases: (i) the use of an arbitrary cofactor, (ii) the ab-
sence of PTMs, (ii) the use of an arbitrary tau segment.
Therefore, it remains today unclear how much of the
atomic arrangements found in recombinant filaments is
biologically relevant.
When extracting aggregates from brain, trypsin resistant
cores show different pattern in gel electrophoresis for
Pick’s disease (PiD), AD, progressive supranuclear palsy
(PSP) and corticobasal degeneration, suggesting different
core composition/structure for each disease [148].
The recent technological breakthroughs of cryo-EM
have allowed to solve two structures of tau aggregates, ex-
tracted from AD- and PiD-affected human brains [40, 44].
These structures represent major advancements in the
field as they provide the first high-resolution molecular
architectures of the tau filament cores extracted from
human tissues. The AD protofilament core is similar for
PHFs and SFs and is composed of R3 and R4 repeat
domains as well as 10 residues in the C terminus region
(306–378), and exhibit a Greek-key conformation [44],
reminiscent of the α-synuclein fibril structure [152]. The
core also forms a region of β-helix similar to the confor-
mation identified in the prion-forming domain of HET-s,
in which it plays a crucial role for infectious properties
[159]. The major difference between SFs and PHFs lies in
the interaction between the two protofilaments. It should
be noted that additional electron densities were detected
in the region before R3, strongly suggesting that part of R2
(for 4R tau) or R1 (for 3R tau) is also partially structured
in AD filaments. Similar structural features were found in
several sporadic and inherited AD brains, suggesting that
this structure is a hallmark of AD [41]. The PiD filament
core encompasses AD’s (306–378) and also includes half
of the R1 repeat [40]. The structure shows that the ar-
rangement of the R1 (254–274) segment is not compatible
with the equivalent sequence in R2 (285–305), providing
an explanation as to why PiD aggregates contain only 3R
tau isoform. Although most of the β-sheets in the region
306–354 locally align between AD and PiD, the filament
core from the latter possesses neither a Greek-key shape
nor a β-helix, characteristic of AD filaments. It should be
noted that although cryo-EM provided two well-defined
structures, it does not exclude the existence of other minor
aggregate species, which would be excluded during the
image analysis process.
The high-resolution structures of brain-extracted tau
aggregates reveal that filaments formed by recombinant
full-length tau seem to be different from in-vivo fila-
ments. Indeed, ssNMR and limited proteolysis predicted
immobile and/or protected regions (see paragraphs
above) different from either AD or PiD filament core. It
was notably unexpected to have a structured core extend-
ing beyond the R4 region. This finding suggests that the
widely used K19 and K18 fragments, composed exactly of
the 3 or 4 repeat domains, might not be able to model PiD
and AD filament cores as they lack the C-terminal region
368–378. In addition, it was shown by EPR spectroscopy
that heparin-induced filaments from a tau fragment 255–
441 do not reproduce the large domain folds present in AD
and PiD cores [43]. The authors also demonstrated that
heparin filaments are highly heterogeneous. These differ-
ences between brain-extracted aggregates and heparin-in-
duced filaments were later confirmed and further described
by cryoEM [170].
The difficulty in obtaining biologically relevant struc-
tures with recombinant proteins could in principle be
overcome by seeding aggregation using tissue-extracted
material. Seeding refers to the process by which monomers
are recruited by premade aggregate, therefore multiplying
the quantity of aggregate, either in vitro or in vivo. Al-
though it is generally thought that seeding faithfully propa-
gates the structure of the seed, this assumption has not yet
clearly been demonstrated at high resolution. On the one
hand, cellular seeding assays have showed that the macro-
scopic aspects as well as the patterns of limited proteolysis
of a given strain can be maintained through several seed-
ing generations [75], suggesting the propagation of the
seed structure. On the other hand, different tau constructs
(tau2N4R, K18 and K19) have been shown to form dif-
ferent limited-proteolysis signature, which cannot be pro-
pagated for more than one generation of in-vitro seeding
[111]. The authors suggested that the seeded protein, and
not the seed, determine the pattern of the final filament.
EPR spectroscopy has been used to characterize the popu-
lation of aggregates at high resolution by measuring intra-
molecular distance distributions inside the filament core.
Meyer and coworkers showed that filaments species are
selected through seeding cycles depending on their me-
chanical properties and the environmental conditions
[100]. The same group highlighted a cross-seeding barrier
between different fragments (in particular K18 cannot seed
K19 while K19 can seed K18) that they attributed to con-
formational incompatibility between the seed and the
seeded species [138]. They furthermore showed that the
seeded barrier can be modulated by single-point mutations
in the core domain or by interactions with the N-and
C-terminal tails [100, 163]. It should be noted that in-vitro
seeding is often assisted by a cofactor (RNA or heparin),
which was recently shown to be an essential component of
the filaments as they are necessary to ensure stability of
either seeded or non-seeded filaments [43]. The biological
relevance of these co-factors is not well established, as
there are many potential co-factor candidates in the cellu-
lar environment. Heparan-sulphate proteoglycans were
reported to be associated with AD tau filaments [51],
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although they are not present in the intracellular medium
where tau is mostly found. RNA was also shown to be
sequestered in tau fibers from several tauopathies [50].
Other proteins might also be potent co-factors such as
α-synuclein [106] and even nuclear pore proteins [38].
Tau fragments and aggregation
Tau truncation plays an important role in AD pathology
[113]. Truncated tau proteins were initially identified as
constituents of the pronase-resistant PHF core [165, 166],
and it has been suggested that tau truncation drives the
pathological conversion of wild-type tau at neuritic pla-
ques [83]. Caspase activation associated with tau trunca-
tion led to tau aggregation in tau transgenic mice and
expression of a tau fragment cleaved at Asp421 (mimic-
king caspase truncation) into wild-type mice led to the ap-
pearance of intracellular aggregates [32]. Intriguingly,
gingipain proteases secreted by Porphyromonas gingivalis,
a pathogen involved in chronic periodontitis and able to
invade the brain, have been proposed to affect tau by
direct gingipain proteolysis as well as gingipain activation
of human proteases that act on tau [36].
In vitro, C-terminal truncated tau at Glu391 or at Asp421
have a higher propensity to aggregate than full-length tau
when using an aggregation inducer [1, 45, 168]. A truncated
form of tau has been identified in AD brain tissue which
extends from residue 297 to residue 391, known as dGAE
[70, 166]. The antibody mAb423 can be used to identify the
specific fragments which terminate at Glu391 [60], and has
been shown to bind to intra- and extracellular NFTs in AD
brain tissue [98, 112, 139]. The presence of this truncated
tau form was confirmed using MS analysis for pronase-un-
treated PHFs extracted form AD brain (Braak stage V: [21]).
This resolved the long running debate as to whether tau
truncation is a result of pronase treatment, or whether it oc-
curs naturally in disease [173].
Polyanions such as heparin have been widely used to pro-
duce tau aggregates for in vitro studies [15, 18, 51, 157].
However, recent work using circular dichroïsm (CD)
revealed that heparin interacts directly with a drug
that was produced by TauRx Therapeutics called leuco-
methylthioninium [3], thus developing a new heparin-free
in vitro model became essential. In addition, heparin-in-
duced filaments (see above) were found structurally differ-
ent from those in AD brain [43].
A new in vitro model system was developed to pro-
duce aggregates from the truncated PHF-core tau frag-
ment, dGAE, using physiological conditions and without
any additives [3, 4]. The resulting filaments closely
resembled PHFs found in AD brain (Fig. 2), sharing a
similar periodicity of 65–80 nm [4, 142]. Furthermore,
the preparation produces a subset (about 10%) of SF-like
filaments, similar to the ratio found from tissue extrac-
tion [44]. dGAE includes the PHF core region identified
in the recently reported PHF structure [41, 44]: residues
323–335 of R3 and 354–369 of R4. Thus, this in vitro
model will help researchers in the field to better under-
stand the tau misfolding process into PHFs and SFs and
the molecular mechanism of tau propagation.
The role of disulphide links in tau assembly into PHF
remains still unclear in full-length tau and in various trun-
cated tau fragments [66]. Full length tau in COS cells
(fibroblasts from monkey kidney tissue) has been reported
to form two types of dimer, one cysteine-dependent and
the other, cysteine-independent [129]. Similarly, dGAE is
able to form both dimer types [4]. Variants of full-length
tau (C291A/C322A) and truncated tau dGAE (C322A)
have been shown to be able to form filaments [4, 129].
Importantly, the self-assembly and elongation of the fila-
ments formed by dGAE is enhanced under reducing con-
ditions, signifying that the cysteine found at position 322 is
not required to form a disulphide bond for assembly of this
truncated region [4]. This is backed by the structural de-
tails of AD isolated PHF which show Cys322 to be buried
in the interior of the structure [44], in contrast with the
PiD fold where it is exposed to solvent [40]. This suggests
that disulphide bond formation is not favourable to form
AD PHF. In addition, inhibition of tau aggregation using a
small molecule, leuco-methylthioninium, was found to be
cysteine-independent [3], confirming that disulphide bond
formation is not necessary for tau assembly.
Tau phosphorylation and aggregation
Tau phosphorylation is physiological and regulates, among
many interactions, the tubulin polymerization capacity of
tau, to maintain the dynamic character of MTs in normal
Fig. 2 Negative stain EM image of in vitro PHFs produced from
dGAE in additive-free conditions at pH 7.4 and 37 °C [4]
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physiological conditions, while tau protein found in PHF
is hyperphosphorylated [55]. In pathological conditions,
the aggregation of tau is commonly described as being a
consequence of tau hyperphosphorylation [5, 158]. The ini-
tial characterization was performed by mass spectrometry
(MS) on PHFs isolated from patients and showed an aver-
age of 20 modified phosphorylation sites compared to an
estimated four to five for the soluble protein [56, 62, 103].
In addition, in vitro tau aggregation assays performed by
addition of polyanionic molecules, such as heparin, is
proposed to mimic the seeding effect of phosphorylated tau
on the unphosphorylated protein [6]. Finally, phosphory-
lated tau, extracted from brain of AD affected patients, or
in vitro phosphorylated by rat brain extract, was shown to
be more sensitive to aggregation in in vitro assays, com-
pared to the unmodified wild-type protein [5]. From these
early results, an attractive model of the impact of phospho-
rylation on tau pathogenesis was proposed: hyperpho-
sphorylated tau would detach from the MTs and aggregate,
phosphorylation initiating both aspects.
Although quite seductive, this model does not recapitu-
late all recent results, and although it has its merits, it is
probably still a simplified view of the impact of tau phos-
phorylation on its aggregation propensity. Indeed, hyper-
phosphorylated tau, obtained by in vitro phosphorylation
with recombinant ERK kinase (15 phosphorylated sites),
rat brain extract (18 phosphorylated sites) [123] or
obtained from recombinant expression in insect cells (10
or 20 phosphorylation sites) is not significantly more sus-
ceptible to in vitro aggregation than its wild-type counter-
part [149]. In the case of ERK-phosphorylated tau, a few
filaments are observed by EM from the pellet of the aggre-
gation assay. However, the aggregation is not detected by
the classical Thioflavin T fluorescence (ThT) associated
with β-sheet aggregate formation in in vitro assay, indica-
ting that the filaments are a minor fraction of tau in the
sample [123]. Accordingly, tau which was highly phos-
phorylated by recombinant expression in insect cells
shows increased oligomerization but not tau fibrillization
per se [149]. The observation that in vitro aggregation
propensity of the in vitro hyperphosphorylated tau is low
does not exclude that it could be a trigger in a cellular
context. Indeed, in cellular context additional elements
are in play [42] some depending on Tau phosphorylation
status, such as interaction with co-factors [50, 51],
increase in local concentration due to detachment from
the MTs [7] and/or deficient degradation [126], as well as
Tau proteolysis (see preceding paragraph).
In addition, not only the number of phosphorylation
sites, but also phosphorylation positions should be consi-
dered, as not all phosphorylations are equivalent. Most
likely a specific combination of phosphorylation sites lies
at the basis of tau becoming oligomerisation/aggregation
prone [154], although the exact combination is unknown.
Keeping this point in mind, a decrease phosphorylation of
tau, globally or at some sites, is compatible with an in-
crease aggregation, depending on which sites are affected.
Moreover, tau is described to misfold on its pathway
of aggregation, although the definition of what is a mis-
folded IDP is not straightforward. Some data indicate
early conformational changes that could be early stages
of misfolding taking place. For example, the MC-1 or
Alz50 antibodies [24] recognize conformational epitopes
and detect abnormal tau in early stages of AD. Pseudo-
phosphorylations (replacement of Ser and Thr residues
by Glu residues) to reproduce the AT8 (the AT8 epitope
is defined in this study as a combination of pSer199,
pSer202 and pThr205), AT100 (pThr212 and pSer214),
and PHF1 (pSer396 and pSer404) epitopes were used to
evaluate the impact of the phosphorylation on tau global
conformation based on distance measurements from
FRET-pairs. A more compact global fold was found com-
pared to the wild-type, increasing contact between the N
and C-terminal regions (paper-clip fold), better reprodu-
cing the conformation recognized by the conformational
antibody MC-1 that targets AD-tau [71]. A recent study
based on cross-linking coupled to MS probed the structural
differences between seed-competent or inert tau monomers,
including tau monomers purified from AD and control
brains. In these seed-competent monomers, the amyloido-
genic peptides PHF6(*) were more accessible compared to
inert (unable to seed aggregation) purified tau monomers
from control brain [101]. Shielding the PHF6(*) sequences
in the inert monomer was attributed to a preferential hair-
pin conformation of tau around these regions. This study
was in agreement with earlier work based on EPR spec-
troscopy showing that exposure of tau to aggregation-pro-
moting cofactor heparin opens up and exposes PHF6(*)
regions [39]. These studies suggest a structural origin for
the initiation of tau aggregation with conversion of tau
monomer from an inert to an aggregation-prone form that
could be viewed as an early misfolding intermediate.
In view of these data, and at the molecular level, two
points should be considered to refine the concept of the
impact of tau phosphorylation on its susceptibility to
aggregation: 1/ the effect of specific pattern of phosphory-
lation and 2/ the impact of these phosphorylation events,
not only on the electrostatic character of tau, but also on
tau local structure and global fold.
With these points in mind, the impact of phosphoryl-
ation on Ser202 and Thr205 was investigated using NMR
spectroscopy. pSer202 and pThr205 are part of the epitope
for the well-known AT8 monoclonal antibody used in
many studies to detect what is defined as a pathological tau
protein. What was observed for the AT8-phosphorylated
tau is the formation of a particular dynamic turn conform-
ation, which is stabilized by a hydrogen bond from the
phosphate of the pThr205 residue side-chain to the amide
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proton of Gly207. The turn conformation is further stabi-
lized by Arg209 and Arg211 residues that face the pSer202/
pThr205 residues with Gly207 located in the middle of the
positively and negatively charged sequences, inducing back-
bone flexibility [46]. Tau protein showing this pattern of
phosphorylation, in combination with absence of phosphor-
ylation of the Ser262 residue to avoid interference, is not
more sensitive to aggregation than the wild-type protein
[35]. However, combined phosphorylation at the Ser202/
Thr205/Ser208 sites, together with absence of phosphoryl-
ation of the Ser262 residue, yields a tau sample that forms
filaments, as observed by ThT fluorescence and EM, and
this triple phosphorylation state of AT8 epitope alone is
sufficient to induce aggregation of tau in vitro [35]. This
triple phosphorylation pattern was suggested to represent a
better epitope for the AT8 monoclonal than the double
Ser202/Thr205 phosphorylation [89]. The crystal structure
of the complex of antibody with a pSer202/pThr205/
pSer208 phosphorylated tau peptide showed no turn con-
formation of the bound epitope. Accordingly, in solution,
no turn-like conformation was detected for the
triple-phosphorylated AT8 epitope. Whether the conform-
ation could be part of the increased susceptibility to aggre-
gation was investigated using a mutated tau protein with
Gly207 replaced by a Val residue exhibiting a bulky,
Cβ-branched side chain. This mutation disrupts the forma-
tion of the dynamic turn, even in the presence of pSer202/
pThr205. Interestingly, susceptibility to in vitro aggregation
of a tau fragment containing the Gly207Val mutation is in-
creased compared to the pSer202/pThr205 or unpho-
sphorylated tau protein. These experiments show that a
conformational change induced, either by a mutation (al-
though Gly207Val mutation has never been found in any
tauopathy) or a specific phosphorylation pattern, could alter
the aggregation propensity of tau, and a large number of
phosphorylated sites is not required to change this propen-
sity. It might be that not only the additional charges, but
also the subtle impact on tau dynamic structure is an im-
portant parameter. The molecular mechanism by which a
dynamic turn located at the AT8 epitope could prevent in
vitro tau aggregation (in the absence of heparin inducer) re-
mains to be defined. It might also not be the only pattern
of phosphorylation that could have this protective effect.
To reconcile these in vitro data with the body of research
conducted in the cellular context is not straightforward.
First, the AT8 can recognize both the double pSer202/
pThr205 and triple pSer202/pThr205/pSer208 phosphoryl-
ation pattern that showed differential effect on tau aggrega-
tion. Secondly, AT8 positive tau species are modulated by
other phosphorylation, and, for example, phosphorylation
of Ser262 prevents in vitro aggregation [133], whatever the
status of the AT8 epitope (2 or 3 phosphorylations).
Nevertheless, the structural studies show a facet of
the complex impact of tau phosphorylation on
aggregation. Although tau is disordered, it can indeed
be described as misfolded at the global and local
level, due to specific phosphorylation.
Zinc binding and tau aggregation
Zinc, the most abundant trace metal in brain, is known
to play an important regulatory role both in a number of
physiological processes, including neuronal growth and
signal transduction, and in the pathogenesis of several
neurodegenerative diseases such as AD [104, 160].
In physiological processes, zinc ions are usually involved
in maintaining structure and function of hundreds of pro-
teins, including enzymes of all known classes, transcription
factors, receptors, and signalling proteins. It has even been
reported that zinc was able to induce some level of struc-
ture formation in intrinsically disordered tau protein
(Fig. 3). Indeed, CD spectra of tau0N4R isoform showed
that zinc acts as a strong promoter of protein confor-
mational changes [65]. Further analysis of these CD spec-
tra using CAPTO tool [164] revealed significant increase
in β-sheet content upon zinc binding, from 1% in the
absence of zinc ions to 5 and 18% in the presence of
0.25 μM and 0.5 μM, respectively. This is also in-line with
dynamic light scattering data presented at EuroTau
meeting 2018 obtained on tau2N4R, which demonstrate a
reduction in tau hydrodynamic radius in solution upon
zinc binding, from 12.2 to 8.8 nm [127]. Such tau compac-
tion and gain of structure may be explained by location of
amino acids implicated in zinc chelation. Indeed, zinc ions
are chelated by Cys291, Cys322 and probably by His330,
His362 as shown using tau (244–372) fragment and its
mutants [102]. Chelation by these residues, located in
R2-R3 repeats, pulls together distant regions of tau and
induces its altered conformation (Fig. 3). This was con-
firmed by performing Isothermal Titration Calorimetry
(ITC) to monitor zinc binding to tau fragments with
mutated cysteine and histidine residues. The experiments
revealed a stoichiometry close to 0.5, indicative of tau frag-
ment dimerization and of the absence of intramolecular
chelation of zinc. Another study based on ITC measure-
ments on Zn binding to tau2N4R or its cysteine mutants
[64] suggested additional zinc binding sites. ITC analysis of
tau2N4R interaction with zinc, presented at Eurotau
2018, confirmed the existence of one high (N = 1.0 ±
0.1; Ka = 2.0 ± 0.5 × 106 M− 1) and of three low affinity
binding sites (N = 3.2 ± 0.3; Ka = 5.9 ± 1.7 × 104 M− 1)
[127]. The high affinity site most probably corresponds to
the one described previously [102] in tau (244–372) frag-
ment, formed by two cysteines and two histidines from R2
and R3 domains (Fig. 3). Since the three auxiliary sites
were not detected in tau (244–372) fragment, they could
be located in N- and/or C- terminal regions, which have
many potential zinc chelating amino acids. Even if we now
have evidence regarding the specific tau regions implicated
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in zinc binding, the impact of zinc binding on tau physio-
logical functions (including binding to tubulin) remains
poorly understood. A recent study showing that zinc ions
binding to tau affects its interaction with DNA offers a
first step towards a better understanding of the functional
aspects of Zn-binding [14].
While in many cases zinc acts as an integral component
of the protein structure, it is also known for its ability to
destabilize the structure of a number of proteins (e.g.
NCS-1, TDP-43) [47, 151]. If not the causative agent, zinc
is found implicated in the development of proteinopathies
as a factor favouring aggregation. An impact of zinc bind-
ing on tau aggregation was previously shown in vivo, in
cells and in vitro. Indeed, recent studies demonstrated that
zinc exacerbates tau pathology in a mouse model [28] and
directly regulates tau toxicity in Drosophila tauopathy
model [65]. Moreover, it was shown that high concentra-
tion of zinc dramatically accelerates aggregation of full-
length human tau and increases its toxicity in neuronal
cells [64]. Several studies have addressed the question of
whether zinc impacts on tau aggregation leading to PHF
formation in vitro [64, 65, 102], yet it should be noted that
they were carried out in the presence of artificial aggrega-
tion inductors such as heparin or congo red. Recently it
was shown that these inducers that are classically used to
stimulate PHF formation actually lead to filaments that
have a different structure from those found in vivo [43].
On the contrary, turbidimetry results presented in
EuroTau2018 showed that in the absence of heparin,
zinc is able to induce a temperature-dependent rever-
sible oligomerization of tau [127]. The obtained
amorphous oligomers were not amyloid-like (ThT
negative and no aggregates are observed by EM), and
dissociated instantly following zinc chelation or a
temperature decrease. At this stage it is not clear whether
this newly identified Zn-induced oligomerization mechan-
ism is part of the early stages that may lead to PHF forma-
tion, or it may be part of a concurrent pathway. In any
case, a better understanding of this process at the molecular
level and the role it plays in cell should not be overlooked
when searching for new strategies to fight neurodegenera-
tive diseases.
Of mice and men
Age-related neurodegenerative disorders, including AD are
largely human-specific pathologies. As a matter of fact, the
human brain seems particularly susceptible to develop tau
pathology leading to neurodegeneration [67]. Transgenic
mice are frequently used as animal models for studying
tauopathies and AD despite the fact that they do not readily
develop the full set of neuropathological and/or clinical
phenotypic features observed in the human pathology [96].
Nevertheless, although far from perfect they have been very
useful in dissecting specific molecular pathways involved in
these pathologies as well as for the preclinical evaluation of
potential therapeutic agents. Most of these murine models
require overexpression of human wild-type or mutant tau
in order to develop significant tau pathology. Wild-type
mice do not develop tau fibrillary pathology but mouse tau
can be recruited in a small proportion into aggregates
formed in human tau-overexpressing transgenic brains [9].
Fig. 3 a Domain structure of tau2N4R with the location of potential zinc chelators shown in sticks (Cys, His, Asp, Glu). b Scheme of zinc chelation
by the main binding sites located in R2 and R3 domains. c Hypothetical scheme of reversible zinc-induced aggregation
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Besides the inherent anatomical and cellular differences
between the human and mouse brain, one main difference
between humans and mice is that the expression of tau iso-
forms varies in the adult brain. While adult human brain
contains almost equal amounts of tau 3R and 4R isoforms,
only 4R isoforms are expressed in the adult wild-type
mouse brain [10]. Intriguingly, despite this divergence in tau
isoform ratios between mice and humans, protein primary
sequences are highly conserved between both species (88%
identity for the longest tau isoform), particularly within the
MTBR (98% identity) [95]. The greatest divergence, how-
ever, appears at the N-terminus where humans have a motif
spanning residues 18 to 28, which is absent from the mouse
tau sequence [121]. Tau amino-terminal region appears to
be involved in the formation of the paper-clip conformation
under physiological conditions [114].
This 18–28 primate-specific motif of unknown function
has recently been reported to mediate tau interaction with
a number of neuronal proteins in a species-specific man-
ner [145]. It is worth mentioning that this motif does not
include any phosphorylation sites, as the Tyr18 residue
long known to be phosphorylated by Fyn tyrosine kinase
to mediate tau-plasma membrane interaction [81], remains
present in both human and mouse sequences. Interes-
tingly, two closely adjacent, flanking regions to the 18–28
motif in human tau have been described to interact with
plasma membrane-binding annexins and thus modulate
tau subcellular localization [48].
Prion-like propagation of tau pathology involves the
release of tau molecules into the extracellular space,
uptake by neighboring cells and seeded aggregation of
soluble proteins. Long believed to be a consequence of
neuronal death, extracellular tau released from healthy
neurons appears however to be a physiological process
that might be disrupted in diseased brain [97]. Thus, there
is increasing evidence to strongly suggest the involvement
of extracellular tau species as the main agent in the propa-
gation of neurofibrillary lesions and spreading of tau
toxicity throughout different brain regions in these dis-
orders [52, 107]. On the other hand, a growing body of evi-
dence has accumulated in recent years to demonstrate a
crucial role for the amino-terminus in tau aggregation,
spreading, dendritic localization and signaling [84].
Actually, overexpression of tau in neuronal and non-neur-
onal cells leads to increased tau levels in the extracellular
medium (reviewed in [118]). Furthermore, the various tau
isoforms show different rates of tau release, whereby the
N-terminal region appears to contribute to tau release from
the cell to the extracellular space [31, 74, 96].
More recently, a full-length human tau lacking the
18–28 motif in the N-terminal region of human tau
mentioned above (tau2N4R-Δ18–28) has been shown to
be less efficiently secreted compared with wild-type tau
when overexpressed in neuronal and non-neuronal
cultured cells [132]. In addition, affinity chromatography
analysis looking for proteins specifically interacting with
that particular human tau motif identified End Binding
(EB) proteins (members of the MTs plus-end tracking
protein family) as binding partners. Moreover, while
overexpression of EB proteins leads to an increase of tau
secretion, EBs downregulation using siRNAs reduced
human tau release. The authors suggest a possible cross-
talk between tau and EB proteins in distal axons in neu-
rons in which tau would contribute to proper EBs
subcellular localization while EBs might favor tau release
outside the cell.
Thus, the presence of the human-specific 18–28 motif
at the tau N-terminal region might facilitate tau secretion
and further propagation of pathology. Studying the under-
lying mechanisms of tau release will provide further
insight into its function in physiological and pathological
conditions that may lead to the identification of relevant
therapeutic targets and the development of novel thera-
peutic agents for these devastating disorders.
A novel panel of tau monoclonal antibodies, rendering
new insights in tau structure and fluid diagnosis
A N-terminal truncated fragment of tau, broadly defined as
the N-terminal part of tau combined with the proline-rich
region and devoid of the repeat domain and C-terminus
[16, 99, 130], is now a well-established biomarker that aids
in the current set-up of new clinical criteria for AD diagno-
sis. Advances in MS, such as FLEXITau [88], demonstrate
that tau isoforms, defined by specific PTMs, might also
help in the development of tau isoform-specific assays for
tauopathies [144]. Furthermore, the recent identification of
seed-competent soluble tau monomers [101] may lead to
tau conformation-specific assays that would be instrumen-
tal in tau-specific targeted therapy developments. Thus,
set-up of tau molecular assays of antigen-antibody interac-
tions will be essential to advance the use of tau both as fluid
marker, and as therapeutic target, in major tauopathies.
Several tau immuno-assays, such as Innotest, Roche
Elecsys, Fujirebio Lumipulse, MSD and EuroImmun
enzyme-linked immunosorbent assay (ELISA) are cur-
rently subjected to harmonization efforts and commutabil-
ity studies [11]. The EuroImmun ELISA is based on
monoclonal tau antibodies raised against tau2N4R
expressed in humanized yeast models [128]. The clinical
value of this assay has been demonstrated in several stud-
ies [34, 147] and the monoclonal antibodies are also used
to explore the potential interest of detecting tau circulat-
ing in plasma [94, 119]. Equal amounts of 3- and 4-repeat
tau are found in cerebral cortex, while expression of tau is
roughly two times higher in gray matter compared to
white matter and cerebellum. Because assembly of tau is
concentration dependent, regional variation in expression
could favor its assembly. In cerebrospinal fluid (CSF), 3-
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and 4-repeat tau are only a minor fraction of the total
protein content and thus isoform-specific immuno-assays
require ultra-sensitive technology, such as immuno-PCR.
Such assays could potentially aid in the differentiation of
4-repeat tauopathies from other tauopathies [87]. In a
renewed effort to isolate conformational tau antibodies, an
antibody with a high affinity for exon 3 (the insert N2, Fig.
3) was isolated, named 18F12. While the potential patho-
logical role of N2-containing tau is still subjected to pre-
clinical scientific research [84, 172], the absence of
N2-containing tau in the 4-repeat specific tauopathy, ar-
gyrophilic grain disease (AGD) [124], suggests that
N2-specific tau ELISA for CSF might be able to differenti-
ate AGD from other tauopathies.
Peptide scanning demonstrates that a major determi-
nant of the 18F12 epitope lies in tau insert N1 (Fig. 3).
While Western-blot and ELISA results demonstrate an
exquisite specificity of 18F12 for N2-specific tau iso-
forms, peptide mapping (18-mers with an overlap of 16
amino acids) have shown a major antigenic determinant
of the 18F12 lies in the C-terminus of N1 (and not in
N2). This epitope overlaps with the recently identified
epitope of a similar high-affinity antibody, PT18. PT18’s
epitope was defined as the three last amino acids of N1
and five amino acids of N2 insert in an independent
characterization of N2-specific monoclonal antibodies
[153], using a slightly modified approach of peptide
mapping. Thus N2-specific antibodies most likely re-
quire a specific conformation of the N1-N2 junction for
optimal recognition of N2 tau isoforms. While further
work is needed to understand the conformational aspect
of the 18F12 epitope, the fact that exon 3 expression is
always associated with exon 2 presence supports a con-
formational affinity aspect. Since the monoclonal anti-
body 18F12 had a high affinity, a simple tau ELISA was
built based on 18F12 as coating antibody and a N-terminal
tau antibody, ADx204, allowing detection of N2-specific
tau in CSF. A clinical study in several clinical groups of
tauopathies, including AGD, is underway.
Tau is a protein with many PTMs and while all
methods to quantify tau have their biases and limita-
tions, widely used sandwich immunoassays are defined
by the epitopes of the capturing and detector antibodies
used in the assay. Therefore, as our data illustrate, a
more precise description of tau antibodies used in diag-
nostic assays is needed and several studies suggest that
this is feasible [27, 89, 136, 169]. Additionally tau pro-
tein is not only present as a soluble full-length protein
[130], but also as truncated and oligomeric/fibrillar
forms. Thus immuno-assays measuring these latter
forms should consider epitopes specific for the frag-
ments and target exposed epitopes in case of specific
conformations because some epitopes might be buried
due to a particular conformation.
To define the added clinical value of novel specific tau
immuno-assays with a specific context-of-use, e.g. differen-
tiation of tauopathies, comparing established tau immuno-
assays with the novel tau assay will be needed. Finally, de-
pending on the specificity of the novel tau antibodies (e.g.
conformational or PTM-dependent), sensitive MS, such as
described above (FLEXITau [88], XL-MS [101]), will be
needed to validate the specificity of antibodies and assays
for its targeted conformation or PTM. Combining techno-
logical advances with specific clinical cohort (con-
text-of-use) studies [108, 117] indeed has recently led to
exploring the amyloid ratio in plasma as potential surrogate
for amyloid Aβ-deposition in preclinical stages of AD.
Imaging of tau aggregates
Until recently, post-mortem examination of brain tis-
sues was the only means available for the direct evalu-
ation of the changes occurring in the brain of AD and
non-AD tauopathy patients. Thanks to molecular neu-
roimaging techniques such as positron emission tomog-
raphy (PET) applied with specific radiopharmaceuticals
for PHFs (see [134] for a recent review), tau pathology
can now be detected, characterized and quantified in
the living human brain [26].
Considering the first-generation tau PET ligands, the
first fluorine-18 (18F) tracer with tau binding capacity was
18F-FDDNP. However, the compound also binds to
β-amyloid and suffered from a lack of selectivity [77].
Meanwhile, more-selective tracers have become available.
Carbon-11 (11C) PBB3, allows tau imaging in AD and
non-AD tauopathies such as corticobasal syndrome. How-
ever, the 11C label is less ideal, as it limits widespread use
due to its short half-life of 20min [137]. Other tau tracers
were recently developed such as F18-AV1451 (aka
F18-T807, Flortaucipir; Avid Radiopharmaceuticals) or
THK5351. F18-AV1451 has demonstrated promising
results and showed increased tau binding in AD. Early
ex-vivo work demonstrated that F18-AV1451 selectively
binds to tangles in post-mortem AD brain tissue [92].
Coupled with PET, F18-AV1451 binding is higher in
patients with AD dementia or with mild cognitive im-
pairment than in clinically normal older adults [72].
The first direct comparison of post-mortem tau path-
ology with in vivo regional F18-AV1451 uptake has just
been published [140]. This study is based on a single
patient, a man with early onset AD caused by a
presenilin mutation. Results showed that in vivo tau
tracer retention strongly correlated with both neuritic
and intrasomal tau pathology and total tau burden, but
not with amyloid plaques, at autopsy.
As expected from neuropathological data [109], tau-PET
signal better predicts brain and cognitive dysfunctions
than amyloid-PET [120] and the regional distribution of
tauopathy closely matches the brain hypometabolism
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observed using Fluorodeoxyglucose PET [57, 116] (Fig. 4).
Tau-PET signal also closely correlates with total tau and
181p-tau concentrations in the CSF [25, 78]. Given the
close relationship between tau deposition, impaired cogni-
tion and neuronal injury, tau-PET is able to provide sig-
nificant additive information to clinical diagnosis and
amyloid-PET imaging and offers a complementary tool to
help in discriminating between different pathologies, and
possibly, between different tauopathies. Besides offering
in-vivo images, the ability to image the presence and
spatial extent of tau deposition also opens the possibility
of tracking the progression of tau pathology over time [68]
and detecting early changes in cognitively unimpaired in-
dividuals [59, 61]. In this respect, it has the potential to
serve as a biomarker for disease severity or neurodegenera-
tion. Moreover, the development and efficient usage of
tau-directed therapeutics will be highly dependent on the
presence or absence of tau and on means to identify those
patients best suited for the therapy, so the utility of such
disease-modifying drugs are dependent on early and accur-
ate detection of tau. Tau-PET represents as well a
non-invasive method to evaluate the efficacy of treatments
with the potential to reduce tau load.
At EuroTau 2018, longitudinal tau-PET data from the
Harvard Aging Brain study were presented [30, 58]. In
clinically normal older individuals, changes in tau-PET sig-
nal were shown to correlate with cognitive decline. While
an association between change in amyloid and change in
tau was also observed, the direct relation between change
in amyloid and change in cognition was rather weak [61].
The data presented advocate for sequential changes in
preclinical AD from amyloidosis to tauopathy to cognitive
deficits. This proof-of-concept study demonstrates the
feasibility of tracking tau pathology in normal adults.
Limitations were however reported for some of these
investigational first generation tau PET imaging agents
concerning off-target binding in several brain regions,
such as basal ganglia or choroid plexus. Particularly,
off-target binding to Monoamine oxidase A (MAO-A)
has been described for F18-AV1451 [155] or to MAO-B
for THK5351 [110]. The presence of monoamine oxi-
dases within several brain regions limits the interpret-
ation of PET imaging results with these tracers. MAO-A
is mostly only expressed in basal ganglia but MAO-B is
expressed in cortex [110]. F18-AV1451 also suffers from
off-target binding on neuromelanin present in the chor-
oid plexus of the temporal horn of the lateral ventricles,
which makes it difficult to evaluate hippocampal signal
properly [80].
The second-generation of tau PET ligands is under de-
velopment with the objective of breaking the limits of
previously reported tau PET agents. These novel second-
generation tau tracers currently investigated clinically
include F18-RO6958948 (Roche), F18-GTP1 (Genen-
tech), F18-MK-6240 (Merck/Cerveau) and F18-PI-2620
(Life Molecular Imaging). F18-PI-2620 data were pre-
sented at EuroTau 2018.
F18-PI-2620 was discovered in a research collabor-
ation between Piramal Imaging (now Life Molecular Im-
aging) and AC Immune SA. Preclinical pharmacological
Fig. 4 Tau PET image in a patient with AD ( Mini Mental State Examination= 20/30), demonstrating close association between tau pathology (top)
and cerebral glucose metabolism (FDG-PET, bottom). Images were acquired at Saint-Luc University Hospital (UCLouvain, Belgium)
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studies indicate specific binding of F18-PI-2620 to patho-
logical tau [146]. F18-PI-2620 shows high affinity for
aggregated tau in AD brain homogenate competition-as-
says and PHF preparations. Autoradiography studies using
human brain sections showed specific binding of
F18-PI-2620 in autopsy-confirmed AD tissue sections
from Braak stages I to VI, as well as to tau deposits in PSP
brain tissue. F18-PI-2620 binds to both tau isoforms 3R
and 4R and demonstrates high selectivity over β-amyloid,
α-synuclein, MAO-A and MAO-B. F18-PI-2620 also
showed low off-target binding in competition assays and
autoradiography studies using brain tissue from non-de-
mented controls. Moreover, in microPET imaging studies
in mice and non-human primates, F18-PI-2620 showed
high brain uptake and fast wash-out.
Based on the available promising preclinical data of
F18-PI-2620 the ex-vivo studies have been extended to first
in-human evaluations [146]. In AD subjects, PET images
of F18-PI-2620 showed a tau distribution pattern expected
from typical histopathology tau-spread [22]. In contrast to
the uptake seen with the β-amyloid PET tracer NeuraCeq,
F18-PI-2620 showed an asymmetric uptake pattern in the
temporal lobes, sparring of the motor cortex and asymmet-
ric uptake in the frontal lobe (Fig. 5). Highest signals were
observed in the temporal cortex, extending into the frontal
cortex in the most severe cases. Standard uptake value ra-
tio (SUVr) time curves suggested a plateau of the signal oc-
curring 60–90min post-injection with resultant SUVrs in
abnormal regions up to four. Clinical data in non-demen-
ted control subjects showed robust initial brain uptake and
fast wash-out from the brain. F18-PI-2620 did not exhibit
an increased tracer uptake in choroid plexus, striatum,
amygdala or other regions of non-demented control
subjects as seen with first generation tau tracers, as well as
no age dependency. Non-invasive quantification of
PI-F18-PI-2620 uptake (SUVr at 60–90min post injection)
provided significant discrimination between non-demented
control and AD subjects. AD subjects showed significantly
higher uptake than in non-demented control subjects in
temporal lobe, parietal and cingulate cortex. Moreover, ex-
cellent test-retest variability has been demonstrated and
confirmed the utility of F18-PI-2620 to evaluate change of
tau deposition in longitudinal studies.
Given the role of tau protein in the pathology of AD
and other non-AD tauopathies, neuroimaging tau PET
biomarker offers the potential to improve our under-
standing of the pathological process in AD and other
tauopathies. Beyond the major progresses that such im-
aging tool offers for research on these pathologies, the
ability to image tau in in vivo brain brings relevant clin-
ical perspectives.
PET imaging appears as a useful tool for detecting the
presence and spatial extent of tau deposition in in-vivo
brains and offers the potential to improve our understand-
ing of the molecular mechanism of neurofibrillary dege-
neration, to predict and track disease progression and to
accelerate the development of rational therapies for AD
and non-AD tauopathies.
Conclusions
Recently, significant advances have been made in under-
standing tau structure and aggregation. The recent inte-
rest in immuno-therapies targeted against tau [69] require
a good definition of what should be targeted by the
assayed antibodies. Many disappointing trials could prob-
ably be avoided from a better definition of tau structure
and related (dys)functions. Similarly, to be able to relate
tau detection to a specific form is essential. Many studies
still rely on the good old AT8 antibody to assess the level
of tau pathology in cells or tissues. In this regard, imaging
has also offered impressive progress that will be critical to
assess any results coming from therapeutic intervention
Fig. 5 Comparison of tracer uptake patterns of F18-PI-2620 targeting tau and Neuraceq targeting β-amyloid plaques
Fichou et al. Acta Neuropathologica Communications            (2019) 7:31 Page 11 of 17
on the tau pathway. In this field, it will also be crucial to
know what is traced.
While instrumentation advancements have allowed re-
cent breakthroughs in structural biology of amyloids, there
are still major fundamental challenges to solve. For
example, what are the molecular factors that determine the
convergence toward a given strain/structure? How can one
reproduce the brain-derived filament structures with re-
combinant protein? While cryoEM has shown that a given
tauopathy is characterized by a specific aggregate structure,
it remains to be shown that a given structure is sufficient
to trigger a specific disease. In other words, do the tau
aggregate structures carry all the pathological information,
as the prion denomination suggests, or are there other sys-
temic factors required?
In addition, the causal relationship between tau hyper-
phosphorylation and aggregation in neuropathology re-
mains to be demonstrated and to date, there are only a
limited number of studies that have explored this relation-
ship. A better definition of the pattern(s) of tau phosphory-
lation that might affect its conformation and lead to the
aggregation path is worth the efforts, as it could help both
diagnostic and therapeutic development by defining the
species of tau that could be considered as targets for
immune-detection or immune-intervention.
All these questions can only be addressed by bringing
together the various approaches, such as NMR for fle-
xible Tau forms and Cryo-EM for the most rigid forms
or fluid immuno-diagnosis coupled to brain imaging re-
search. The EuroTau meeting will continue to provide
such opportunities.
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